Delays between presentation and treatment could have a significant effect on breast cancer mortality. The authors hypothesized that patient, physician, and system barriers are all responsible for treatment delays. Therefore, a study was conducted to define prevalent barriers to treatment from the patient's perspective. A modified 43-item Likert-scale questionnaire was administered to patients with clinical stage III locally advanced breast cancer (LABC) who had experienced a delay in treatment of 3 months or more. Between
In the United States, breast cancer will affect approximately 1 in 8 women, resulting in an estimated 132,340 new cases of invasive breast cancer and 39,620 deaths in 2013. 1 Despite efforts to improve early detection, too many patients still present for treatment after extended delays from the initial onset of symptoms. 2 According to one definition, delay is considered a period of at least 3 months from symptom appearance to seeking medical care. 3 Approximately one-fourth of women with breast cancer symptoms have at least a 3-month delay in care. 1 Delay in care is likely to affect prognosis and survival. 4 As an example, increased tumor size is associated with a greater likelihood of regional and distant metastasis, and long-term survival is worse with each 5 mm of growth. [5] [6] [7] [8] In an effort to reduce cancer disparities, interventions to improve breast cancer screening have been successfully implemented. 9, 10 However, the authors observed that a disproportionately high number of patients continued to present with locally advanced breast cancer at City of Hope National Medical Center, an NCIdesignated Comprehensive Cancer Center (COHCC) located in Southern California, where access to health care resources is readily available. The authors hypothesized that 3 major primary roots for delays originate primarily from the patient, physician, or health care system. The study intended to determine the perceived barriers to treatment among a cohort of women presenting at COHCC with locally advanced or inflammatory breast cancer who had experienced a 3-month or greater delay in initiation of oncologic treatment from the time of the initial event that led them to seek treatment. 
Methods

Study Population
This pilot study enrolled patients from an ethnically, socioeconomically diverse population drawn primarily from a 50-mile radius area encompassing greater Los Angeles, San Bernardino County, and surrounding areas. The sample size was based on COHCC's accrual patterns and was specified in advance, with primary consideration for the time allotted for the study. All patients signed an informed, voluntary, COHCC Internal Review Board-approved consent form. Eligible patients were recruited between October 2008 and January 2010 who fulfilled the following criteria: 1) were diagnosed with histologically proven clinical stage III and/or inflammatory breast cancer (defined clinically as having one-third or more of the breast surface area involved with inflammatory changes); 2) male or female; 3) had no history of prior malignancy; 4) were 18 years of age or older; 5) experienced a delay of 3 months or more in initiation of oncologic treatment from the time of the symptom occurrence/reason for seeking treatment; and 6) were proficient in English. During the accrual period, 153 patients presented with locally advanced stage III (LABC) or inflammatory breast cancer. Forty-three patients (28.1%) were eligible and, of sequentially screened patients, 40 (93.0%) agreed to participate. Participants were approached either at the first appointment with the oncologist or at the first chemotherapy treatment.
Statistical Considerations
This study used a prospective descriptive study design. Nichols et al's 11 3-phase model was used to better categorize the delay: 1) the interval between first noticing a symptom and first consulting a doctor (ie, patient delay); 2) the interval between first consultation with a doctor and referral (ie, practitioner delay); and 3) the time between referral and diagnosis (ie, system delay).
Assessment Tool
Patients were asked to complete a modified 43-item Likert-Scale Barriers Scale for Oncologic Treatment Questionnaire developed to explore perceived barriers. The questionnaire was developed based on previous studies with qualitative data from patient and focus group interviews. [12] [13] [14] [15] [16] [17] [18] Responses were rated on a 5-point scale of "strongly agree" through "strongly disagree," relative to the barriers presented ( Table   1 ). The dates associated with the symptom occurrence/reason for seeking treatment were obtained from the participants. Dates of the biopsies, followup appointments, imaging studies, referrals, and demographic data were obtained from the participants' medical records, allowing the investigators to determine where the delays occurred and to assess which kinds of delays were most frequent and of longest duration.
The responses to the questionnaire were tabulated using frequency tables and constructed histograms for graphic representation. The analyses were limited to descriptive statistics. This pilot cohort had a lack of sufficient inferential power for correlating demographic and clinical factors with subject-reported barriers, particularly when subjects identified multiple types of barriers simultaneously.
Results
Patients
Forty eligible and evaluable patients (median age, 49 years; range, 30-78 years) were consecutively enrolled over 12 months and completed the questionnaire. Of these, 32.5% were Caucasian, 47.5% Hispanic, 12.5% African American, and 7.5% Asian. This is somewhat different from the ethnic distribution of all patients with LABC seen at CO-HCC during the enrollment period, which included 59.5% Caucasian, 28.8% Hispanic, 7.8% African American, and 10.5% Asian. The characteristics of the study population are shown in Table 2 . Patients experienced a range of 16-to 77-week delays (median, 24 weeks) to initiating chemotherapy treatment. For 75% of patients, the diagnosis of breast cancer was made at an outside institution. Of the patients diagnosed at an outside institution, 6.7% had Medicare, 46.0% had state medical insurance, 40.0% had private insurance, and only 6.7% had no insurance. The insurance distribution of the aforementioned participants is different from that of the patients diagnosed at COHCC, among whom 30% had Medicare, 20% state medical insurance, 40% private insurance, and 10% no insurance.
Barriers to Treatment as Reported by Patients
Patient Barriers: Patients reported multiple barriers in this category; however, the most commonly reported patient barrier, based on participants re- 
Physician-Related Barriers
The mammogram was negative so I thought everything was fine.
The physician did not think the lump was cancer.
The physician did not think it was necessary to do a biopsy.
The physician did not refer me for further evaluation.
There were delays in the referral to the oncologist.
The biopsy was negative so I thought everything was fine.
System-Related Barriers
I had difficulty with the insurance company approving the mammogram.
There were delays in scheduling diagnostic tests.
There were delays in getting test results.
There were delays from the insurance company in authorizing tests, treatment, or doctor visits.
Patient-Related Barriers
I worried that mammograms cost too much and I did not have insurance.
I was too busy with work or school to get a mammogram or see a doctor.
I had difficulty taking time off from work.
I had difficulty finding transportation.
I just did not want to get any further tests.
I worried about the possibility of losing my breast.
I worried that I could not afford the copayment.
I thought I would have difficulty finding child care.
I thought I was too old to need a mammogram.
I thought I was too young to need a mammogram.
I did not want to think about the breast changes/lump. I did not think the breast changes/lump was important or urgent.
I thought the changes/lump would go away. I thought the lump was an infection, a muscle strain, or related to my period.
I thought my significant other or family would not be supportive of future treatments.
I did not make it to the follow-up appointments after I first sought medical attention.
I waited for the usual or scheduled return visit to get my results.
I had other more important health problems that prevented me from getting a mammogram.
I had emotional problems that prevented me from getting a mammogram.
I had sick family members to take care of so I couldn't attend to my breast problem.
My family would have made fun of me if I had a mammogram.
I could not remember to schedule a mammogram.
I thought having a mammogram would expose me to unnecessary radiation.
I was afraid that having a mammogram would be too painful.
I was afraid to have a mammogram because I thought having it would take too much time.
I did not know how to go about getting a mammogram.
I thought a woman doesn't need a mammogram unless she has symptoms. I was afraid to have a mammogram because I did not understand what would be done.
I was afraid to have a mammogram after finding the breast changes/lump because I thought it might mean something was wrong.
porting "strongly agree" or "agree," was "patient waited for the previously scheduled standard appointment to get the results instead of requesting an earlier appointment" (47.5%). Approximately 38% of patients did not seek medical care because they were concerned about losing their breast. Other patients delayed care because of the perception that their breast symptoms were from infection or muscle strain, or related to their menstrual cycle (25.0%); that the lumps would go away (28.5%); that the lumps were not important or urgent (20.0%); or they did not want to think about the breast changes or lumps (20.0%). Roughly one-fourth of the patients (22.5%) were worried that they could not afford the copayment. Other barriers, such as access to transportation, lack of insurance, inconvenient physician office hours, child care problems, lack of family support, other medical and emotional problems, and inability to take time off from work, continued to be present but were not as frequently reported, with each of these barriers being reported less than 20% of the time. Physician Barriers: The most commonly reported physician barriers per patient reports were "the physician of initial contact did not believe their breast lump/ symptom was related to cancer" (20%) or did not think a biopsy was necessary (15%). Ten percent of the physicians did not refer the patient for further evaluation. System Barriers: The most prevalent system barriers were "delay in scheduling diagnostic test" (40.0%) and "delays from insurance company in authorizing tests, treatment, or doctor visits" (30.0%). Less frequent were delays in referral to the oncologist (21.1%) and delays in getting the test results (17.5%). Only 12.9% of the patients reported having a negative initial biopsy. Table 3 shows the ranges and medians for the time between symptom occurrence/reason for seeking treatment and appointments related to seeking treatment, and between appointments marking various stages of evaluation. The range for overall time elapsed between symptom occurrence and beginning of chemotherapy was 16 to 77 weeks (median, 24 weeks). The time between the first symptom occurrence/reason for seeking treatment and the first appointment ranged from 0 to 72 weeks (median, 12 weeks), with 0 indicating that the patient had a diagnostic or physician appointment the same week the symptoms occurred. Of the 40 participants, 22 had an appointment within 3 months or less. The time to achieving histologic diagnosis was 3 to 72 weeks (median, 15 weeks), with 15 patients having a biopsy within 3 months or less. Most of the patients had almost every one of the combinations of delays delineated in Table 3 .
Time Lapsed Between Occurrence of Symptoms and Stages of Evaluation:
Discussion
This study investigated the variables associated with a 3-month or greater delay leading to the eventual Unexpectedly, 55% of the delays observed were patient-related only, with an additional 27.5% of the delays being a combination of patient and system or physician delays. The most frequent causes included patients waiting for a previously scheduled standard/ annual appointment to be evaluated instead of requesting an earlier appointment to address their concerns, or patients' concern about losing their breast. These findings contrast strikingly with previous studies in which only 9% to 45% of patients were found to have patient-related delays, with the most cited reason why women waited to seek medical attention being fear of finding cancer. Although these fears continue to cause major barriers for women (17.5% in this study), the authors can speculate that their patient population experienced fewer system barriers than seen in previous studies. Physician delay has been reported for 6% to 18% and system delay for up to 61% of patients with breast cancer who experienced therapeutic delay. 12, 19 In this study, only 15% of the participants experienced physician and/or system delays, with an additional 27.5% experiencing a combination of patient and system or physician delays. The most commonly reported physician barrier was the physician of initial contact not believing that the breast lump/symptom was related to cancer, with 15% of physicians making a judgment that a biopsy was not necessary because of the unlikely possibility of finding cancer. Delays in scheduling diagnostic tests and insurance continued to be system barriers that lengthened the delay in oncologic treatment.
A limitation of this study is the difficulty establishing the exact date of symptom onset, because the authors relied on the date of symptom occurrence/ reason for seeking treatment as recalled by the patients at the time they entered the study. Because of the single-institutional nature of the study, another limitation is the sample size: it is too small to determine whether the delays to seeking treatment differed from those in previous studies or among ethnicities evaluated. Despite the small sample size, however, the findings clearly show the existence of barriers to seeking and receiving oncologic treatment among women with access to specialists.
Conclusions
These findings suggest that delay by the patient in seeking medical care immediately after the onset of breast symptoms is a major barrier to oncologic treatment, as evidenced by the length of patient delays being longer than those caused by the provider or system. These results indicate that the system and physician barriers are not as prevalent as reported in other studies. Hence, although it is important to continue to address the physician and system barriers that remain, a need exists to direct greater resources toward educating patients and the population about the importance of assertively seeking early medical assessment, and to share information about the significant advances yielding improved survival and quality of life outcomes, so that patients, family, and society can overcome the fear of treatment.
Larger studies clearly are essential to confirm the findings of this pilot study and gain further insight into the barriers and disparities to oncologic treatment. This understanding will, in turn, allow the development of interventions to decrease delays in treatment, which should reduce breast cancer mortality. Signifies that the patient saw physician the same week they noted the breast symptoms/reasons leading to diagnosis.
